Chugai Pharmaceutical | Sustainability Performance

https://www.chugai-pharm.co.jp/english/

Develops and sells prescription pharmaceuticals, primarily in oncology and immunology.

1925

Japan

5,001 - 10,000 employees

Pharmaceuticals

$1B - 10B in revenue

$1B - 10B in profitability

Submit or report inaccurate data Download Company Insights

Sustainability Ranking & Industry Benchmark

#1732

Overall

#88

in Japan

#48

in Pharmaceuticals

Sustainability Maturity

Sustainability Intent

Available in
Scale package

Access

Industry Rank

95 out of 312

Overview

Environmental

Carbon emissionsEnergy consumptionWaste managementWater managementAir and land impactNature and biodiversityNature riskClimate risk

Social

Diversity and inclusionPay gapsHealth and safetyExternalities

Governance

TargetsSDG ImpactESG scores and exclusionsB-corp & CDP

Financial Data

Business performanceCapital & innovationAnalyst projections

View similiar companies

Rici Healthcare

Japan, Hospital & Health Care, Hospital & Health Care

Santen Pharmaceutical

Japan, Hospital & Health Care, Pharmaceuticals

Takeda Pharmaceutical

Japan, Hospital & Health Care, Pharmaceuticals

CO2 scope 1 + 2

116.8K CO2e tonnes, 2024

Aligned

Renewable energy

48% 2024

Waste generated

3.4K tonnes, 2024

Leading

Female engagement

43% 2025

Laggard

Externalities

11.3M $, 2024

Leading

Market cap

1.7Qa $, 2026▼1% YoY

Revenue

8.4B $, 2025▲6.9% YoY

R&D intensity

14.91% 2025

Intensity

Greenhouse gas intensity Scope 1, 2 (tCO₂e /$M)

Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)

Energy consumption (direct) intensity (MWh /$M)

Water consumption intensity (m³ /$M)

Waste generation intensity (tonnes /$M)

Industry Benchmark

13.9

B/M 13.9

130.6

B/M 114.3

31.4

B/M 35.7

47.1

B/M 219.7

0.4

B/M 0.3

Controversy level

Very Low

Low

Noticeable

High

Severe

Download Controversy Analysis

Chugai Pharmaceutical Co Ltd (Roche 59.89% controlled), Japanese major pharma (Hemlibra hemophilia, Actemra rheumatoid arthritis, Ronapreve COVID antibody cocktail), has faced multiple Japanese class actions over alleged inadequate disclosure of RocheChugai relatedparty transactions affecting Japanese institutional minority shareholders, plus the contested 2024 sustained share price volatility amid Japanese pharma customer demand normalization.

Carbon emissions breakdown

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Energy consumption breakdown

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Biodiversity impact

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Waste management

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	-	-	-	*******	*******

Water management

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	-	-	-	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	-	-	-	*******	*******

Air pollution

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	-	-	*******	-	*******

Land use

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Diversity & inclusion

Reveal data for 3 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Pay gap breakdown

Reveal data for 1 credit

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	-	-	-	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	-	-	-	-	*******
*******	*******	*******	*******	*******	-	-	*******

Health & safety

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	-	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Externalities

Reveal data for 1 credit

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

SBTi targets and commitments

Target	Status	Temperature alignment	Year
Near-term target	Targets set	1.5°C	2030
Long-term target	Not disclosed	-	-
Net-zero	Not disclosed	-	-
Business Ambition 1.5°C	Not disclosed	-	-

Target details

Chugai Pharmaceutical Co. , Ltd. commits to reduce absolute scope 1 and 2 GHG emissions 60% by 2030 from a 2019 base year. Chugai Pharmaceutical Co. , Ltd. commits to increase annual sourcing of renewable electricity from 0% in 2019 to 100% by 2025. Chugai Pharmaceutical Co. , Ltd. also commits to reduce absolute scope 3 GHG emissions 30% by 2030 from a 2019 base year.

SDG impact (historical)

Reveal data for 5 credits

KPI	Metric	Year
		2019	2020	2021	2022	2023	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Reporting

Sustainability Report

Available

Sustainability employees

Total sustainability employees

Available in
Scale package

Access

Controversy level

Very Low

Low

Noticeable

High

Severe

Download Controversy Analysis

Chugai Pharmaceutical Co Ltd (Roche 59.89% controlled), Japanese major pharma (Hemlibra hemophilia, Actemra rheumatoid arthritis, Ronapreve COVID antibody cocktail), has faced multiple Japanese class actions over alleged inadequate disclosure of RocheChugai relatedparty transactions affecting Japanese institutional minority shareholders, plus the contested 2024 sustained share price volatility amid Japanese pharma customer demand normalization.

Chugai Pharmaceutical | Sustainability Performance

Sustainability Ranking & Industry Benchmark

Sustainability Maturity

Sustainability Intent

Available in Scale package

View similiar companies

Carbon emissions

Renewable energy

Renewable electricity

Intensity

Female engagement

Waste

Controversy level

Carbon emissions breakdown

Energy consumption breakdown

Climate risk

Nature risk

Production loss

Revenue at risk

Assets exposed to sensitive locations

Biodiversity loss in km²

Biodiversity loss in CO2e

Potential species loss

Biodiversity impact

Waste management

Water management

Air pollution

Land use

Diversity & inclusion

Pay gap breakdown

Health & safety

Externalities

Revenue & EBITDA

Margin trends

R&D intensity

Return on invested capital

Analyst revenue estimates & actuals

Environmental policy coverage

SBTi targets and commitments

Target details

Overall score

Environment

Social

Governance

Exclusion screening

CDP Scores

SDG impact

SDG impact (historical)

Reporting

Sustainability employees

Available in Scale package

Chugai Pharmaceutical | Sustainability Performance

Sustainability Ranking & Industry Benchmark

Sustainability Maturity

Sustainability Intent

Available in Scale package

View similiar companies

Carbon emissions

Renewable energy

Renewable electricity

Intensity

Female engagement

Waste

Controversy level

Carbon emissions breakdown

Energy consumption breakdown

Climate risk

Nature risk

Production loss

Revenue at risk

Assets exposed to sensitive locations

Biodiversity loss in km²

Biodiversity loss in CO2e

Potential species loss

Biodiversity impact

Waste management

Water management

Air pollution

Land use

Diversity & inclusion

Available in
Scale package

Available in
Scale package

Available in
Scale package

Available in
Scale package